Having listened to the FDA briefing, these folks clearly struggle to balance the cost benefit analysis issue with a side effect that they acknowledge is rare and may not in fact be connected to the vaccine itself. They’re basically saying they can afford this pause because Pfizer/Moderna are plentiful in supply but you should go ahead and take the J&J if a doctor advises it due to the benefit of avoiding the risks of COVID. That puts J&J in second class status and discourages its use.
I will say that the reporters did ask good questions at this presser, better than I expected.
What this tells me is that if things weren’t going so well with Pfizer and Moderna, this pause would not likely have been announced or would’ve been rolled out differently. We should hope we don’t hear of issues with Pfizer and Moderna. We’re nearing that inflection point towards where Israel is now.